Cargando…
VEGF-B antibody and interleukin-22 fusion protein ameliorates diabetic nephropathy through inhibiting lipid accumulation and inflammatory responses
Diabetic nephropathy (DN) is considered the primary causes of end-stage renal disease (ESRD) and is related to abnormal glycolipid metabolism, hemodynamic abnormalities, oxidative stress and chronic inflammation. Antagonism of vascular endothelial growth factor B (VEGF-B) could efficiently ameliorat...
Autores principales: | Shen, Yilan, Chen, Wei, Han, Lei, Bian, Qi, Fan, Jiajun, Cao, Zhonglian, Jin, Xin, Ding, Tao, Xian, Zongshu, Guo, Zhiyong, Zhang, Wei, Ju, Dianwen, Mei, Xiaobin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7838033/ https://www.ncbi.nlm.nih.gov/pubmed/33532185 http://dx.doi.org/10.1016/j.apsb.2020.07.002 |
Ejemplares similares
-
Simultaneous blockade of VEGF-B and IL-17A ameliorated diabetic kidney disease by reducing ectopic lipid deposition and alleviating inflammation response
por: Cao, Zhonglian, et al.
Publicado: (2023) -
Interleukin-22 ameliorated renal injury and fibrosis in diabetic nephropathy through inhibition of NLRP3 inflammasome activation
por: Wang, Shaofei, et al.
Publicado: (2017) -
A novel fusion protein consisting of anti-ANGPTL3 antibody and interleukin-22 ameliorates diabetic nephropathy in mice
por: Ma, Qianqian, et al.
Publicado: (2022) -
Interleukin-22 Attenuated Renal Tubular Injury in Aristolochic Acid Nephropathy via Suppressing Activation of NLRP3 Inflammasome
por: Wang, Shaofei, et al.
Publicado: (2019) -
Interleukin-22 drives a metabolic adaptive reprogramming to maintain mitochondrial fitness and treat liver injury
por: Chen, Wei, et al.
Publicado: (2020)